BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:THN391 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of THN391\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06814730-782@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:THN391: Phase 1 readout est. (NCT06814730)
DESCRIPTION:THN391\, phase 1\, Alzheimer's Disease.\nStudy: A Study to Asse
 ss THN391 in Subjects With Alzheimer's Disease\nEstimated primary completi
 on: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/th
 n391#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06814730
URL:https://assetmemo.bio/drug/thn391#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06701721-782@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:THN391: Phase 1 readout est. (NCT06701721)
DESCRIPTION:THN391\, phase 1.\nStudy: A Study Intravitreal THN391 in Diabet
 ic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.\nEs
 timated primary completion: 31 March 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/thn391#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06701721
URL:https://assetmemo.bio/drug/thn391#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
